netoglitazone
netoglitazone structure
|
Common Name | netoglitazone | ||
|---|---|---|---|---|
| CAS Number | 161600-01-7 | Molecular Weight | 381.420 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 599.5±30.0 °C at 760 mmHg | |
| Molecular Formula | C21H16FNO3S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 316.4±24.6 °C | |
| Symbol |
GHS09 |
Signal Word | Warning | |
|
MCC-555-induced NAG-1 expression is mediated in part by KLF4.
Eur. J. Pharmacol. 637(1-3) , 30-7, (2010) Peroxisome proliferator-activated receptor gamma (PPARgamma) plays a central role in cell differentiation, metabolism and tumorigenesis. We have investigated the therapeutic properties of 5-[[6-[(2-fluorophenyl)-methoxy]-2-napthalenyl]-methyl]-2,4-thiazolidin... |
|
|
Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat.
Int. J. Exp. Pathol. 84(2) , 83-9, (2003) The Zucker Diabetic Fatty (ZDF) rat is a model of impaired insulin sensitivity arising from hyperphagia owing to a mutation in the leptin receptor. In time, young ZDF rats, which are not initially diabetic, develop impaired pancreatic beta-cell function leadi... |
|
|
Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.
Exp. Cell Res. 310(1) , 196-204, (2005) Histone deacetylase-inhibitors affect growth and differentiation of intestinal epithelial cells by inducing expression of several transcription factors, e.g. Peroxisome proliferator-activated receptor gamma (PPARgamma) or vitamin D receptor (VDR). While activ... |
|
|
Quantitative determination of MCC-555, a novel insulin sensitizer in beagle dog plasma by high-performance liquid chromatography with fluorescence detection.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 835(1-2) , 35-9, (2006) A sensitive high-performance liquid chromatographic method with fluorescence detection has been developed for determination of MCC-555 (5-[[6-(2-fluorbenzyl)-oxy-2-naphy] methyl]-2,4-thiazolidinedione) in beagle dog plasma. Sample preparation was done by prot... |
|
|
[KRP-297, MCC-555].
Nihon Rinsho. 59(11) , 2200-6, (2001) KRP-297 and MCC-555, which are being developed in Japan as thiazolidinediones, uniquely bind and activate peroxisome proliferator-activated receptors(PPAR). KRP-297, unlike other thiazolidinediones, effects on not only PPAR gamma but also PPAR alpha. Furtherm... |
|
|
[Insulin-sensitizing agents].
Nihon Rinsho. 57(3) , 688-94, (1999)
|
|
|
PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.
Am. J. Physiol. Endocrinol. Metab. 293(6) , E1736-45, (2007) Peroxisome proliferator-activated receptor-gamma (PPARgamma) regulates adipocyte genes involved in adipogenesis and lipid metabolism and is the molecular target for thiazolidinedione (TZD) antidiabetic agents. Adipose triglyceride lipase (ATGL) is a recently ... |
|
|
Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Br. J. Pharmacol. 125(8) , 1708-14, (1998) 1. We examined the effect of chronic (21 days) oral treatment with the thiazolidinedione, MCC-555 ((+)-5-[[6-(2-fluorbenzyl)-oxy-2-naphy]methyl]-2,4-thiazo lid inedione) on metabolic status and insulin sensitivity in obese (fa/fa) Zucker rats and Zucker Diabe... |
|
|
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat
Bone 38(1) , 74-84, (2006) Thiazolidinediones are effective anti-diabetic drugs that improve insulin sensitivity through the activation of the nuclear receptor and adipocyte-specific transcription factor, peroxisome proliferator-activated receptor gamma (PPAR-γ). Recent evidence sugges... |
|
|
The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment.
Br. J. Pharmacol. 125(4) , 767-70, (1998) 1. Young (6-week-old) pre-diabetic Zucker Diabetic Fatty (ZDF) rats displaying impaired glucose tolerance (IGT), moderate hyperglycaemia and hyperinsulinaemia were treated with the novel thiazolidinedione, MCC-555, for 28 days, during which time beta-cell fai... |